Welcome to our dedicated page for Incyte Genomics news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte Genomics stock.
Incyte Genomics Inc. (Symbol: INCY) is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of proprietary therapeutics, with a primary focus on oncology. Headquartered in Wilmington, Delaware, Incyte employs over 625 professionals across its management, discovery, clinical development, and commercial teams.
The company’s flagship product, Jakafi, is a groundbreaking treatment for rare blood cancers and graft versus host disease, developed in partnership with Novartis. Incyte has also made significant strides with its other marketed drugs, including Olumiant for rheumatoid arthritis (licensed to Eli Lilly), Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. Additionally, Incyte's first dermatology product, Opzelura, received approval in 2021 for atopic dermatitis and in 2022 for vitiligo.
Incyte’s pipeline includes a wide array of innovative oncology and dermatology programs, demonstrating their commitment to addressing serious unmet medical needs. The company's strategic collaborations with major pharmaceutical firms further support the clinical development and global commercialization of its compounds.
Incyte’s financial health and robust portfolio position it strongly to continue improving patient lives while building sustainable value for its shareholders. For the latest updates on Incyte’s projects and developments, visit their corporate website at www.incyte.com.
Eli Lilly and Incyte announced that the FDA granted an Emergency Use Authorization (EUA) for baricitinib in combination with remdesivir for hospitalized patients with COVID-19 requiring supplemental oxygen. This is the second Lilly therapy to receive EUA for COVID-19 treatments. In clinical trials, the combination showed a 12.5% reduction in recovery time and a 35% decrease in mortality compared to remdesivir alone. Despite this progress, the use remains temporary, pending further evaluation of baricitinib's efficacy and safety.
Incyte (Nasdaq: INCY) announced the presentation of over 40 abstracts related to its oncology portfolio at the 62nd American Society of Hematology Annual Meeting (ASH 2020) from December 5–8, 2020. Notable studies include the Phase 3 REACH3 study of ruxolitinib for chronic graft-versus-host disease and various presentations on myeloproliferative neoplasms. The company expressed gratitude for ASH's virtual format, emphasizing its commitment to addressing significant medical needs in oncology.
On November 2, 2020, Eli Lilly and Incyte announced positive long-term data for Olumiant (baricitinib) to be presented at ACR Convergence 2020. Key findings show that 27.5% of csDMARD-IR and 18.4% of bDMARD-IR patients achieved Low Disease Activity after 2.3 years. In a 5-year study, low rates of radiographic progression were maintained across various RA patient populations. No new safety concerns were identified, reinforcing Olumiant's long-term efficacy and safety for moderate to severe rheumatoid arthritis treatments.
Eli Lilly and Incyte announced new data for baricitinib presented at the 29th annual EADV Congress, showcasing its long-term efficacy in treating moderate to severe atopic dermatitis. In the BREEZE-AD3 Phase 3 study, over 40% of patients maintained clear skin after 68 weeks of treatment. Baricitinib received EU approval for adult patients who qualify for systemic therapy. The safety profile aligns with previous studies, reinforcing its potential role in managing this chronic condition ultimately impacting approximately 1-3% of adults worldwide.
Eli Lilly and Incyte presented data for baricitinib at the virtual Fall Clinical Dermatology meeting from Oct 29 to Nov 1, 2020. The Phase 2 study (BRAVE-AA1) evaluated its efficacy in adult patients with alopecia areata (AA). Results showed significant improvement in patients achieving a SALT score ≤20 at 36 weeks, with the 4-mg dose showing 51.9% improvement versus 3.6% for placebo (p=0.001). Following positive Phase 2 results, Phase 3 trials (BRAVE-AA1 and BRAVE-AA2) have been initiated. The FDA has granted Breakthrough Therapy designation for baricitinib for AA due to unmet medical needs.
Incyte announced positive results from a pooled analysis of two Phase 3 studies, TRuE-AD1 and TRuE-AD2, evaluating ruxolitinib cream for treating mild-to-moderate atopic dermatitis. The studies showed significant efficacy in reducing itch and improving skin severity, as measured by EASI and SCORAD tools. Key findings included 52.6% and 62.0% responder rates for ruxolitinib cream at different concentrations. The safety profile was consistent with previous findings, and an NDA submission to the FDA is anticipated by the end of the year.
Incyte has scheduled its Q3 2020 financial results conference call for November 5, 2020, at 8:00 a.m. ET. The press release will precede the call, available at 7:00 a.m. ET. Investors can access the live webcast and slides through Incyte's investor relations website. Replay options are also provided for both domestic and international calls. The conference ID for the call is 13711777.
Incyte is dedicated to addressing serious medical needs through innovative therapeutics.
Eli Lilly and Incyte announced new data demonstrating that baricitinib, in combination with remdesivir, significantly reduces recovery time for hospitalized COVID-19 patients. The Adaptive COVID-19 Treatment Trial (ACTT-2) revealed a median recovery time improvement from 8 to 7 days, with a 12.5% relative reduction. Notably, mortality rates dropped 35% through Day 29 among patients receiving the combination therapy, particularly benefiting those requiring supplemental oxygen. Lilly is pursuing Emergency Use Authorization from the FDA for baricitinib's COVID-19 treatment.
Nimble Therapeutics has formed a strategic collaboration with Incyte (NASDAQ: INCY) to develop innovative peptide therapies across various disease areas. This collaboration aims to leverage Nimble's advanced peptide synthesis and screening platform to enhance drug discovery. Under the agreement, Nimble will receive an undisclosed upfront payment, research program reimbursements, and potential milestone payments and royalties. Incyte retains exclusive rights to develop and commercialize any resulting peptides, with possibilities for further collaboration on additional targets.
FAQ
What is the current stock price of Incyte Genomics (INCY)?
What is the market cap of Incyte Genomics (INCY)?
What is Incyte Genomics Inc. known for?
Where is Incyte Genomics Inc. headquartered?
What is Jakafi?
Which drugs has Incyte marketed?
What is Opzelura used for?
Does Incyte collaborate with other pharmaceutical companies?
How many employees work at Incyte?
What is Incyte's vision?
How can I get more information about Incyte?